Home > Boards > US Listed > Biotechs > Can-Fite BioPharma (CANF)

Both down ;CANF $5.50 OPLI $3

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
mlkrborn Member Profile
 
Followed By 39
Posts 7,816
Boards Moderated 1
Alias Born 01/04/06
160x600 placeholder
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/24/2020 7:08:15 AM
Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting’ in the NASH Category of the American Associatio... Business Wire - 11/24/2020 7:00:00 AM
Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET Business Wire - 11/23/2020 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/16/2020 7:10:35 AM
Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liv... Business Wire - 11/16/2020 7:00:00 AM
Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020 Business Wire - 11/9/2020 7:00:00 AM
Securities Registration (ads, Immediate) (f-6ef) Edgar (US Regulatory) - 11/6/2020 4:33:40 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/28/2020 4:32:21 PM
Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on Octob... Business Wire - 10/13/2020 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/6/2020 7:42:24 AM
Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis Business Wire - 10/6/2020 7:30:00 AM
Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson’s Treatment of NASH at American Association for... Business Wire - 9/30/2020 7:00:00 AM
Securities Registration (foreign Private Issuer) (f-3) Edgar (US Regulatory) - 9/25/2020 4:38:21 PM
Can-Fite to Participate in Two BioPharma Partnering Conferences Business Wire - 9/22/2020 7:00:00 AM
Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 Business Wire - 9/8/2020 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/8/2020 6:02:34 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/31/2020 7:11:17 AM
FDA Clears Can-Fite to Commence Phase II COVID-19 Study Business Wire - 8/31/2020 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 8/28/2020 4:34:45 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/27/2020 7:11:16 AM
Can-Fite Reports Second Quarter 2020 Financial Results & Provides Clinical Update Business Wire - 8/27/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/25/2020 8:23:48 AM
Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH Business Wire - 8/25/2020 8:09:00 AM
Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET Business Wire - 8/20/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/12/2020 4:30:32 PM
mlkrborn   Monday, 12/30/13 10:12:22 AM
Re: None
Post # of 1597 
Both down ;CANF $5.50 OPLI $3 Can-Fite BioPharma announces top-line results of Phase III Study with CF101 for dry eye syndrome; CF101 did not meet the primary efficacy endpoint (CANF) :

Co announced today that its subsidiary OphthaliX (OPLI) released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.
The patients were randomized to receive two oral doses of CF101 or a placebo, for a period of 24 weeks.
In the study, CF101 did not meet the primary efficacy endpoint of complete clearing of corneal staining, nor the secondary efficacy endpoints. Nonetheless, CF101 was found to be well tolerated.
Global Data estimates that the global market for rheumatoid arthritis therapeutics was $12 billion in 2010 and is projected to reach $18 billion by 2020. The global market for treating psoriasis was $3.3 billion in 2010 and is projected to reach $6.7 billion by 2018, according to Global Data.
OphthaliX is also developing CF101 for the treatment of Glaucoma and Uveitis. The interim data from the ongoing phase II study in Glaucoma is expected to be released during 2014.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences